US Central Lab Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)
US Central Lab Market: by Type (Standalone Central Labs, Integrated Central Labs, Specialty Central Labs, Esoteric Central Labs, Clinical Central Labs, Bioanalytical Central Labs) Application (Oncology, Cardiovascular, Infectious Diseases, Endocrinology, Genetic Disorders, Others), Distribution Channels (Direct Contracts, CRO Partnerships, Hospitals & Clinics, Research Institutes, Diagnostic Centers, Others), Technology (Molecular Diagnostics, Immunoassays, Clinical Chemistry, Microbiology, Hematology, Others), Organization Size (Small, Medium, Large) and By US Historical & Forecast Period (2020-2035) Comprehensive Study 2025
Last Updated: 12-09-2025 | Format: PDF | Report ID:21085 | Author: Mike
The US Central Lab market is experiencing robust expansion driven by advancements in diagnostics and increasing demand for specialized laboratory services. Rapid adoption of molecular diagnostics and growing partnerships with contract research organizations (CROs) are reshaping the landscape. As the healthcare sector seeks efficiency and innovation, US central labs are playing a vital role in clinical trials, drug development, and disease monitoring. Key companies continue to invest in automation and digital transformation, further accelerating market growth through the forecast period.
Latest Market Dynamics
Key Drivers
Rising prevalence of chronic diseases fueling demand for advanced diagnostics, demonstrated by Labcorp’s expanded cardiovascular testing portfolio (2025).
Increasing number of clinical trials and partnerships with CROs, highlighted by ICON Plc
’s strategic alliance with leading pharmaceutical companies (2025).
Key Trends
Surge in adoption of molecular diagnostics for personalized medicine, as seen in Quest Diagnostics’ launch of advanced genomic solutions (2025).
Expansion of digital and automation technologies in lab processes, evidenced by Thermo Fisher Scientific’s AI-driven lab management tools (2025).
Key Opportunities
Untapped potential in genetic disorder diagnostics, with Eurofins Scientific intensifying R&D for rare disease testing in 2025.
Growing need for decentralized and remote laboratory services, as demonstrated by Medpace’s expansion into telemedicine-enabled lab models (2025).
Key Challenges
Operational complexities in integrating advanced technologies across legacy lab networks, experienced by Charles River Laboratories as it upgrades infrastructure (2025).
Compliance and regulatory pressures in maintaining data integrity and patient privacy, highlighted by Covance facing stricter FDA guidelines (2025).
Key Restraints
High capital requirements for automation and digitalization, limiting participation of smaller labs as seen with ACM Global Laboratories (2025).
Shortage of skilled professionals in specialized diagnostic techniques, leading to bottlenecks in service delivery for BioAgilytix Labs (2025).
Standalone Central Labs hold the largest share in the US Central Lab market at 32%, owing to their strong infrastructure and established client base. Integrated Central Labs account for 22%, benefiting from their ability to offer seamless end-to-end services. Specialty Central Labs capture 18%, focusing on disease-specific testing, while Esoteric Central Labs represent 13% with advanced rare diagnostics. Clinical Central Labs follow with 10%, and Bioanalytical Central Labs make up the remaining 5%. The increasing need for quick turnaround times and quality assurance continues to boost these segments, led by ongoing investments in automation and technology.
US Central Lab Market Share by Applications (2025)
Oncology dominates the US Central Lab market with a 38% share, driven by the rise in cancer incidences and the need for complex clinical trials. Cardiovascular applications account for 21%, reflecting higher demand for early disease detection. Infectious Diseases represent 15%, propelled by ongoing investments in pandemic preparedness. Endocrinology comes in at 11%, followed by Genetic Disorders at 9%, and Other applications at 6%. The focus on personalized medicine and increasing clinical research are catalysts for sustained growth across all segments.
The US Central Lab market revenue is projected to grow from $5,200 million in 2020 to $13,900 million by 2035. The surge is attributed to breakthroughs in laboratory automation, an expanding pipeline of clinical trials, and heightened demand for rapid and specialized testing. Year-over-year revenue growth underscores the impact of digital transformation, strategic partnerships, and regulatory support fostering innovation. Oncology and molecular diagnostics are expected to remain the leading segments, contributing substantially to overall market growth.
US Central Lab Market Year-Over-Year Growth (2020-2035)
The US Central Lab market posts a healthy year-over-year (YOY) growth rate, starting at 6.8% in 2020 and peaking at 8.1% in 2025, reflecting robust investment in digital lab solutions and research collaborations. Growth moderates to 7.1% by 2030 and 6.5% in 2035 as the market matures. The initially high YOY rates are linked to increased post-pandemic demand for advanced diagnostics and heightened clinical research activities, while the slight decline toward 2035 indicates industry stabilization.
The Northeast dominates the US Central Lab market, capturing 36% of the share due to its concentration of pharmaceutical hubs and research institutes. The Midwest follows at 27%, driven by significant clinical trial activities. The South holds 22%, while the West accounts for the remaining 15%. These regional variances are shaped by local investments in healthcare infrastructure, academic partnerships, and availability of skilled workforce, ensuring balanced growth across the country.
Labcorp leads the US Central Lab market with a 24% share, driven by a strong nationwide network and diversified diagnostics portfolio. Quest Diagnostics holds 19% on the heels of innovations in genomics. Eurofins Scientific captures 12%, bolstered by advanced research collaborations. ICON Plc and Medpace each account for 9% and 7%, focusing on specialized clinical trial capabilities. Remaining competitors collectively contribute 29%, reflecting a healthy, competitive market landscape.
Pharmaceutical and Biotechnology Companies are the leading buyers with a 41% share, utilizing central labs for clinical trial management and new drug development. Contract Research Organizations (CROs) represent 24%, leveraging comprehensive lab networks for outsourced research. Hospitals & Clinics account for 18%, with Diagnostic Centers at 9%. The remainder, including Research Institutes and Others, constitutes 8%. This buyer distribution showcases the central role played by clinical research and healthcare institutions in US lab market growth.
Study Coverage
Metrics
Details
Years
2020-2035
Base Year
2025
Market Size
7500
Regions
Northeast, Midwest, South, West
Segments
By Type, By Application, By Distribution Channel, By Technology, By Organization Size
June 2024: Labcorp launches a new AI-powered analytics platform for clinical lab data integration across the US.
July 2024: Quest Diagnostics announces expansion of its genomic testing services, targeting rare and inherited conditions.
August 2024: Medpace partners with leading telehealth providers, enabling virtual clinical lab collaborations.
September 2024: ICON Plc secures a multi-year agreement with a major pharmaceutical company to support oncology clinical trials.
October 2024: Eurofins Scientific opens a state-of-the-art biorepository facility to enhance sample management and storage capabilities.
Frequently Asked Questions
About the Author
Mike
Lead Industry Analyst
Mike is a Lead Industry Analyst specializing in market research, industry analysis, and business consulting across Telecommunication. Mike brings a commercially grounded perspective to sectors shaped by changing demand, innovation, and competitive dynamics, helping turn complex market trends into clear strategic insights for business decision-makers. With 10+ years of experience across research, analytics, and strategic advisory roles, Mike has helped organizations translate data into actionable growth strategies.
